Evidence map›Paper›PMID 38243937›Full record

ArticleCurrent computer-aided drug design2025

Molecular Mechanism Analysis of the Effect of Hederagenin Combined with L-OHP on Chemosensitivity of AGS/L-OHP based on Network Pharmacology.

Hongyue Tang, Chao Wang, Chenhao Xing, Guoxin Liang, Chang Guo, Xin Liu, YanJie Li, Mingming Zhang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current computer-aided drug design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hongyue TangGraduate School of Hebei North University, 075000, Zhangjiakou, Hebei, China.ORCID 0009-0007-5157-3887
Chao WangHebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, 050051, Shijiazhuang, Hebei, China.
Chenhao XingGraduate School of Hebei North University, 075000, Zhangjiakou, Hebei, China.
Guoxin LiangGraduate School of North China University of Science and Technology, 063000, Tangshan, China.
Chang GuoGraduate School of North China University of Science and Technology, 063000, Tangshan, China.
Xin LiuGraduate School of Hebei Medical University, 050051, Shijiazhuang, Hebei, China.
YanJie LiGraduate School of North China University of Science and Technology, 063000, Tangshan, China.
Mingming ZhangDepartment of Clinical Medical Research Center, Hebei General Hospital, 050051, Shijiazhuang, Hebei, China.
Hebei North University · CNNorth China University of Science and Technology · CNHebei General Hospital · CNHebei Medical University · CN

Funding

government funded the clinical medical talent training program 2020009
6 · The paper itself

Abstract

AIMS AND

objectivesThis study aimed to evaluate the pharmacological mechanism of Hederagenin (HD) combined with oxaliplatin (L-OHP) in treating gastric cancer (GC) through network pharmacology combined with experimental verification. MATERIAL AND

methodsNetwork pharmacology methods were used to screen potential targets for HD, L-OHP, and GC-related targets from public databases, and the intersection of the three gene sets was taken. Cross genes were analyzed through protein-protein interaction (PPI) networks to predict core targets, and related pathways were predicted through GO and KEGG enrichment analysis. The experimental results were verified by the

resultsKEGG analysis showed that the anti-gastric cancer effect of HD was mediated mainly by PI3K-Akt signaling pathways. The PI3K-Akt signaling pathway containing more enriched genes may play a greater role in anti-gastric cancer. It was observed that for AGS/L-OHP cells jointly treated with HD and L-OHP, their activity, migration and invasion were significantly lower than those treated only using HD or L-OHP group. Moreover, expressions of p-Akt, p- PI3K, Bcl-2, P-gp, and Survivin for the HD+L-OHP group decreased significantly. Results of the

conclusionOur findings suggest that HD may reduce the resistance of AGS/L-OHP cells to LOHP by regulating the PI3K/Akt signaling pathway.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsOxaliplatinStomach NeoplasmsAnimalsCell Line, TumorCell ProliferationHumansMiceMice, Inbred BALB CMice, NudeNetwork PharmacologyOleanolic AcidXenograft Model Antitumor AssaysAntineoplastic AgentshederageninOleanolic AcidOxaliplatinchemosensitivitydrug resistanceGastric cancerhederageninoxaliplatinsignaling pathway.

Identifiers

PMID38243937
PMCPMC12376131
OpenAlexW4391067270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.